GlassScriptPhysician profile
Minh C Shaw
NPI 1558526988
$4,828.86
in general payments reported to CMS, 2019-2025
22 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $176 · 2021: $606 · 2022: $519 · 2023: $762 · 2024: $1,124 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,291.44 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $757.51 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $276.70 | 2022-2025 | Rocklatan, Rhopressa, Argos |
| Harrow Eye, LLC | $256.06 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $229.09 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $228.18 | 2019-2021 | |
| Oyster Point Pharma, INC. | $223.93 | 2023-2025 | Tyrvaya |
| Shire North American Group INC | $179.82 | 2019 | |
| Dompe US, INC. | $174.30 | 2025 | Oxervate |
| Allergan, INC. | $150.31 | 2019-2020 | |
| Astellas Pharma US INC | $146.57 | 2023 | |
| Sight Sciences, INC. | $143.20 | 2022 | |
| Ivantis, INC | $135.38 | 2021 | |
| Kala Pharmaceuticals, INC. | $127.60 | 2021 | |
| Astellas Pharma Global Development | $81.65 | 2024 | Izervay |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $81.33 | 2022-2023 | Tepezza |
| Abbvie INC. | $78.49 | 2022-2025 | |
| Coopervision INC. | $63.42 | 2024-2025 | Synergeyes Contact Lens |
| Amgen INC. | $58.14 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $53.94 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $47.03 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $44.77 | 2019-2025 | Lipiflow System Activator (Disposable) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.